RankAlpha logo
Back to Rankings

NXGL

NexGelF
Nasdaq / Health Care Equipment & Services
Last Price
$3.61-$0.19 (-5.13%)
At close · 2026-11-18
View Chart
Documents
32
Stored
Transcripts
1
Recent loaded
Latest document
2026-11-05
Related article

Document history

Transcripts and related coverage stored for NXGL. Related articles may discuss other companies and are not verified issuer releases.

12 shown
Related articleQuarter not tagged2026-11-05

Teleflex (TFX) Q3 Earnings Surpass Estimates

Zacks
Teleflex (TFX) came out with quarterly earnings of $2.63 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $3.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +36.98%. A quarter ago, it was expected that this medical equipment maker would post earnings of $1.28 per share when it actually produced earnings of $1.76, delivering a surprise of +37.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Teleflex, which belongs to the Zacks Medical - Instruments industry, posted revenues of $567.78 million for the quarter ended September 2026, missing the Zacks Consensus Estimate by 1.04%. This compares to year-ago revenues of $913.02 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Teleflex shares have added about 22.8% since the beginning of the year versus the S&P 500's gain of 12.3%. While Teleflex has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Teleflex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Bu…Read full document

Teleflex (TFX) came out with quarterly earnings of $2.63 per share, beating the Zacks Consensus Estimate of $1.92 per share. This compares to earnings of $3.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +36.98%. A quarter ago, it was expected that this medical equipment maker would post earnings of $1.28 per share when it actually produced earnings of $1.76, delivering a surprise of +37.5%. Over the last four quarters, the company has surpassed consensus EPS estimates three times. Teleflex, which belongs to the Zacks Medical - Instruments industry, posted revenues of $567.78 million for the quarter ended September 2026, missing the Zacks Consensus Estimate by 1.04%. This compares to year-ago revenues of $913.02 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Teleflex shares have added about 22.8% since the beginning of the year versus the S&P 500's gain of 12.3%. While Teleflex has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Teleflex was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $2.07 on $592.09 million in revenues for the coming quarter and $7.22 on $2.28 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 43% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, NexGel, Inc. (NXGL), has yet to report results for the quarter ended September 2026. This company is expected to post quarterly loss of $4.80 per share in its upcoming report, which represents a year-over-year change of -200%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. NexGel, Inc.'s revenues are expected to be $4.19 million, up 43% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Teleflex Incorporated (TFX) : Free Stock Analysis Report NexGel, Inc. (NXGL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Related articleQuarter not tagged2026-11-02

Idexx Laboratories (IDXX) Beats Q3 Earnings and Revenue Estimates

Zacks
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to earnings of $3.4 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.28%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $3.95 per share when it actually produced earnings of $4.27, delivering a surprise of +8.1%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Idexx, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.21 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 2.21%. This compares to year-ago revenues of $1.11 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Idexx shares have lost about 18.5% since the beginning of the year versus the S&P 500's gain of 10.7%. While Idexx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Idexx was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (St…Read full document

Idexx Laboratories (IDXX) came out with quarterly earnings of $3.98 per share, beating the Zacks Consensus Estimate of $3.71 per share. This compares to earnings of $3.4 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +7.28%. A quarter ago, it was expected that this Animal diagnostic and health care company would post earnings of $3.95 per share when it actually produced earnings of $4.27, delivering a surprise of +8.1%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Idexx, which belongs to the Zacks Medical - Instruments industry, posted revenues of $1.21 billion for the quarter ended September 2026, surpassing the Zacks Consensus Estimate by 2.21%. This compares to year-ago revenues of $1.11 billion. The company has topped consensus revenue estimates four times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Idexx shares have lost about 18.5% since the beginning of the year versus the S&P 500's gain of 10.7%. While Idexx has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Idexx was favorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #2 (Buy) for the stock. So, the shares are expected to outperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $3.37 on $1.17 billion in revenues for the coming quarter and $14.81 on $4.72 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Instruments is currently in the top 42% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. One other stock from the same industry, NexGel, Inc. (NXGL), is yet to report results for the quarter ended September 2026. This company is expected to post quarterly loss of $4.80 per share in its upcoming report, which represents a year-over-year change of -200%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. NexGel, Inc.'s revenues are expected to be $4.19 million, up 43% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report NexGel, Inc. (NXGL) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research

Related articleQuarter not tagged2026-08-17

NEXGEL Reports Second Quarter 2026 Financial Results

GlobeNewswire
LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026. The second quarter of 2026 was a period of significant transformation and preparation for NexGel. Following the completion of our transaction with Celularity, Inc. in mid-April, the Company focused on transitioning employees, integrating sales representatives and customer relationships, and aligning our marketing, operations, and branding efforts around the newly formed BioNX Surgical division. These initiatives were designed to support commercial growth, strengthen customer engagement, and advance our strategic partnership with Sequence Life Science, Inc. While progress has been made, our rollout initiatives and expansion into the surgical channel have occurred at a slower pace than originally anticipated. On August 4, Sequence deployed several tissue processing specialists to Celularity's New Jersey facility as part of our previously announced plan to transfer manufacturing technology and future production capabilities to Sequence's facility in San Antonio, Texas. This initiative was established at the outset of the acquisition to address known long-term supply chain constraints and improve manufacturing scalability. While meaningful progress has been made, these supply chain challenges have continued to impact product availability and have contributed to a current BioNX Surgical backlog of approximately $795,000. Q2 revenue totaled $3.69 million, with a net loss of $2.87 million. The reported loss included several non-recurring or non-cash items, including $756,554 of BioNX intangible asset amortization, $273,710 of one-time transaction-related expenses, and $144,495 associated with the strategic recall of all SilverSeal inventory from Amazon. The SilverSeal inventory recall was undertaken to support the product's launch into the hospital market beginning in August. SilverSeal already has established reimbursement A-codes, providing coverage opportunities for both surgical and wound care applications in physician offices, ambulatory surgery centers (ASCs), and hospital settings…Read full document

LANGHORNE, Pa., Aug. 17, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2026 financial results for the period ending June 30, 2026. The second quarter of 2026 was a period of significant transformation and preparation for NexGel. Following the completion of our transaction with Celularity, Inc. in mid-April, the Company focused on transitioning employees, integrating sales representatives and customer relationships, and aligning our marketing, operations, and branding efforts around the newly formed BioNX Surgical division. These initiatives were designed to support commercial growth, strengthen customer engagement, and advance our strategic partnership with Sequence Life Science, Inc. While progress has been made, our rollout initiatives and expansion into the surgical channel have occurred at a slower pace than originally anticipated. On August 4, Sequence deployed several tissue processing specialists to Celularity's New Jersey facility as part of our previously announced plan to transfer manufacturing technology and future production capabilities to Sequence's facility in San Antonio, Texas. This initiative was established at the outset of the acquisition to address known long-term supply chain constraints and improve manufacturing scalability. While meaningful progress has been made, these supply chain challenges have continued to impact product availability and have contributed to a current BioNX Surgical backlog of approximately $795,000. Q2 revenue totaled $3.69 million, with a net loss of $2.87 million. The reported loss included several non-recurring or non-cash items, including $756,554 of BioNX intangible asset amortization, $273,710 of one-time transaction-related expenses, and $144,495 associated with the strategic recall of all SilverSeal inventory from Amazon. The SilverSeal inventory recall was undertaken to support the product's launch into the hospital market beginning in August. SilverSeal already has established reimbursement A-codes, providing coverage opportunities for both surgical and wound care applications in physician offices, ambulatory surgery centers (ASCs), and hospital settings. Management believes the hospital channel represents a significant growth opportunity, with the potential to drive increased sales volume while generating higher gross margins than current distribution channels. In addition, the Company recently launched BioNX Regenerative Eye Health & Aesthetics, a new commercial initiative focused on ocular and aesthetic applications. The platform includes exclusively licensed products from Sequence and is designed to expand BioNX's presence in high-growth regenerative medicine markets. The initiative is being led by Shaun Mullen, an industry veteran with more than 20 years of experience successfully launching and scaling ophthalmic companies and technologies. The Company's recently completed proxy solicitation did not receive sufficient shareholder support for the proposed increase in authorized shares and reverse stock split authority. Management believes the primary reason was an unusually high level of broker non-votes. Because these otherwise routine corporate governance proposals were linked to a proposal to redomicile the Company, brokers were unable to vote uninstructed shares in accordance with management's recommendations. The Company intends to resolicit shareholder approval for the increase in authorized shares and reverse split authority as standalone proposals, without the redomicile component, and has engaged Alliance Advisors as proxy solicitor to assist in the process. Based on shareholder feedback and the expected reduction in broker non-votes, management believes both proposals are well-positioned for approval. The current timeline anticipates completion in late September, well within the timeframe necessary to support the Company's strategic and capital markets objectives. As of June 30, 2026, the Company held approximately $710,000 of restricted cash related to its prior transaction with ATW Partners. Since quarter end, those funds have been released and returned to the Company, and the Company's business relationship with ATW has been concluded. While the integration of the acquired businesses and associated revenue ramp have progressed more slowly than originally anticipated, management remains encouraged by opportunities entering the second half of the year. The Company expects to host an investor update call on or around September 15, 2026, to provide shareholders with a detailed update on operational progress, commercialization initiatives, and expectations for the remainder of 2026. About NEXGEL, INC.NEXGEL is a leading provider of healthcare, beauty, and over the counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Non-GAAP Financial MeasuresCertain non-GAAP financial measures are included in this press release. In the calculation of these measures, the Company excludes certain items, such as amortization of intangible assets, stock-based compensation, tax impact of adjustments, other unusual items and discrete items impacting income tax expense. The Company believes that excluding such items provides investors and management with a representation of the Company's core operating performance and with information useful in assessing its prospects for the future and underlying trends in the Company's operating expenditure and continuing operations. Management uses such non-GAAP measures to evaluate financial results and manage operations. The release and the attachments to this release provide a reconciliation of each of the non-GAAP measures referred to in this release to the most directly comparable GAAP measure. The non-GAAP financial measures are not meant to be considered a substitute for the corresponding GAAP financial statements and investors should evaluate them carefully. These non-GAAP financial measures may differ materially from the Non-GAAP financial measures used by other companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our belief the hospital channel represents a significant growth opportunity, with the potential to drive increased sales volume while generating higher gross margins than current distribution channels and our belief that both the increase in authorized shares and reverse stock split proposals are well-positioned for stockholder approval.. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2025, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contact:Valter Pinto, Managing DirectorKCSA Strategic [email protected]

Related articleQuarter not tagged2026-05-16

Nexgel (NXGL) Q1 2026 Earnings Transcript

Motley Fool
Image source: The Motley Fool. Friday, May 15, 2026 at 12 p.m. ET Chief Executive Officer — Adam R. Levy Chief Financial Officer — Ian Blackman Need a quote from a Motley Fool analyst? Email [email protected] Adam R. Levy: Thank you, Valter, and thank you, everyone, for joining us today. On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid April. Starting with our first quarter results, revenue for the first quarter totaled 2.65 million as compared to 2.81 million for the same period last year. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case which has since been settled. Cash and restricted cash as of 03/31/2026 was approximately $2.1 million. As of today, our cash on hand is $1.8 million. In total, we have raised $13.8 million comprised of $8.8 million received in cash, and $5 million of our convertible note delivered to Cellularity to fund the acquisition and to provide the business with working capital. The first quarter does not include any revenue from our acquisition. In the second quarter, we have already seen sales from Silly George normalize and recover, and we will begin accounting for revenue from our acquisition for about half of the second quarter. The financing for BioNX was led by Sequence LifeScience, with a $5.5 million investment that not only strengthen the financing structure of the transaction, but also aligns us with a partner that enhances our capabilities across manufacturing, product development, and distribution. Importantly, this transaction replaced a financial lender who was seeking a near term exit with a long term strategic partner who is focused on supporting the long term growth and execution of our business. Brian J. Keeser and Kevin Harris, CEO and COO of Sequence LifeScience. Have since joined our board of directors. Brian and Kevin bring deep industry experience, product innovation, and a strong distribution network that will help us grow and expand the p…Read full document

Image source: The Motley Fool. Friday, May 15, 2026 at 12 p.m. ET Chief Executive Officer — Adam R. Levy Chief Financial Officer — Ian Blackman Need a quote from a Motley Fool analyst? Email [email protected] Adam R. Levy: Thank you, Valter, and thank you, everyone, for joining us today. On today's call, I would like to provide an overview of our first quarter 20 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid April. Starting with our first quarter results, revenue for the first quarter totaled 2.65 million as compared to 2.81 million for the same period last year. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case which has since been settled. Cash and restricted cash as of 03/31/2026 was approximately $2.1 million. As of today, our cash on hand is $1.8 million. In total, we have raised $13.8 million comprised of $8.8 million received in cash, and $5 million of our convertible note delivered to Cellularity to fund the acquisition and to provide the business with working capital. The first quarter does not include any revenue from our acquisition. In the second quarter, we have already seen sales from Silly George normalize and recover, and we will begin accounting for revenue from our acquisition for about half of the second quarter. The financing for BioNX was led by Sequence LifeScience, with a $5.5 million investment that not only strengthen the financing structure of the transaction, but also aligns us with a partner that enhances our capabilities across manufacturing, product development, and distribution. Importantly, this transaction replaced a financial lender who was seeking a near term exit with a long term strategic partner who is focused on supporting the long term growth and execution of our business. Brian J. Keeser and Kevin Harris, CEO and COO of Sequence LifeScience. Have since joined our board of directors. Brian and Kevin bring deep industry experience, product innovation, and a strong distribution network that will help us grow and expand the potential of our new acquisition. I am very excited to have them in our corner and I am looking forward to working with them to grow the business. The BioNX portfolio includes 6 established regenerative biomaterial products positioning us squarely within 1 of the fastest growing segments of health care. These are not early stage assets, They are commercial stage products with more than a decade of clinical use, demonstrated real world utility, and already have existing reimbursement pathways. These products are approved in approximately 500 hospitals across The US, and represent a large opportunity for BioNX in several surgical specialties as well as wound care. To lead this effort, we recently appointed Dave Hazard as vice president of sales for BioNX Surgical, who brings more than 13 years of sales leadership across orthopedics, spine, biologics, and joins the company in an important stage in its commercial growth phase. He has a strong track record of building scalable sales infrastructure, and establishing the kind of enterprise partnerships that drive repeatable revenue. His expertise in biologics and commercial execution will be instrumental as we continue expanding operations for our newly formed BioNX division. In addition to our existing products, we currently have 3 510(k) devices in development within our pipeline. These programs represent approximately $4.6 million in invested paid in capital and are targeted for commercialization in 2027, 2026, and 2020. Beyond the products, we have also added an experienced commercial and scientific team. This is an important aspect of the transaction as it meaningfully expands our internal capabilities and strengthens our ability to develop the markets for NEXGEL's own medical devices. This transaction will be transformative not only from a strategic standpoint, but also financially. On a pro forma basis, we anticipate it to approximately triple our annual revenue to roughly $35 million and to be immediately accretive to profitability upon closing. Taken together, the acquisition and our strategic partnership with Sequence represents step change in NEXGEL's trajectory. We are combining a proven hydrogel platform with a portfolio of commercial regenerative products supported by a strategic manufacturing partner. This positions us to accelerate product development broaden our commercial footprint, and pursue new opportunities within the regenerative medicine landscape. Lastly, I am excited to introduce Ian Blackman as our new CFO. Ian is a veteran financial and M&A leader who has been appointed to lead the integration of our acquisition scale the business, and accelerate growth. Our board and senior leadership team is now the strongest it has ever been in our history. We are focused on successfully integrating these assets driving commercial growth and continuing to build a platform that can generate sustained long term growth and profitability. I am looking forward to reporting on our second quarter financial results in August, where we will be able to provide more details into the integration and execution of our BioNX division. With that, I will turn the call over to the operator, and I am happy to take any questions. Operator? Operator: Thank you. If you would like to ask a question, press *1 on your keypad. To leave the queue at any time, press #2. Once again, that is *1 to ask a question. And our first question today will come from Naz Rahman with Maxim Group. Your line is now open. Analyst (Nas Raman): Hi, everyone. Congrats on closing the deal and the progress, and thanks for taking my I just have a few. Now that you have closed the BioNX transaction, how long has the field force, I guess, been out there promoting the product? I realize it is only going to be a limited amount of time. But how long have they been out promoting the BioNX product? And have you seen, like, I guess, in uptick in reception or sales of the products versus their prior run rate under the previous owner? Adam R. Levy: So, okay. 3 parts. I will try to go through them in order. So we were not able to really do a lot preclosing just because of the nature of--we had not closed and it was not our asset. There is a little bit of a lag in terms of getting the Salesforce reengage and going out there. Right? We have our own contracts that have to be approved by legal. We have to do our own training because of various rules like Sunshine Laws. So we are really now just getting the contracts back and guys are going out there. So that is why I kind of framed it as half a quarter. Because now, as of May 15, we are just really getting out there and starting to ramp the sales. And sending out, getting back the contracts changing all the vendors, calling all the hospitals that do not change the account name from Cellularity to BioNX. All of these things are small things that happen in a matter of a few weeks. But they do need to get done before you can really ramp. So we are kind of excited for what May and what June are going to look like. But we are really just getting started. Analyst (Nas Raman): Understood. that is fair. On the tripling of your revenue that you communicated, does that assume at this point that, like, the non-BioNX business or businesses stay flat, or are you assuming any growth there? It seems like that non-BioNX business is basically flat at this point. Adam R. Levy: Yeah. It is. We do not expect it to stay flat. You know, Silly George had a uncharacteristically bad fourth quarter and a kind of a meh first quarter, year over year, down a little bit. So we see already a recovery, in April on that product line. So we think there will be some growth, but we were kind of, you know, modest in that. We have very little growth built in for this particular segment. Analyst (Nas Raman): Got it. And 1 last question, if I may. I guess, what normalized with all the additional sales reps, and the R&D team, how much do you expect operating expenses to be I guess, on a quarterly basis? Or how much do you expect it to increase annually on a normalized basis? Adam R. Levy: So we probably have added, and, our CFO, Ian, is on the call as well. So correct me if I am mistaken in this, Ian. But I think that we have added in fact, why do not I just ask you what we think the operating overhead is? Analyst: Yeah. So it will be an approximate monthly run rate of 500 thousand. All in. Salaries, marketing, and commissions, and so on. Analyst (Nas Raman): Got it. That was helpful. Thanks for taking my questions. Thank you. Operator: And once again, if you would like to ask a question, please press star and 1 on your keypad now. And we will take our next question from Ves Mahallov, as a private investor. Analyst (Ves Mahalow): Thank you for taking my questions, Adam. Good morning. Adam R. Levy: Hi, Ves. Good talking to you again. Analyst (Ves Mahalow): That is. I wanted to ask you about the offering. Is it still open? You just filed an 8-K for another million dollars. Are you still conducting this offering? Is it still open for additional investors? And do you intend to file an 8-Ks and a press release stating when it is completely closed. Adam R. Levy: Yes. We do. And it is pretty much closed. there is a couple of, smaller investors, particularly board members that are kind of coming in at the end. And by the way, now you if you look at the million we filed, they are also a board he is also a board member at this point. So this was really mostly an investor and--kind of, there is a couple of small investors that have been a long term friends of the company. But we will be wrapping that up in the next day or 2, and then we will make an announcement in an 8 k early part of next week. Analyst (Ves Mahalow): Okay. So just want to alert you that there is a, you know, 350 thousand shares sold short. So I think that, you know, this is like a wet blanket on the stock. So the sooner it closes, provided you have got all the money necessary, the better. Just my personal opinion. Adam R. Levy: Understand. Analyst (Ves Mahalow): The next question is, I wanna go back to the legacy business. I mean, could you comment a little bit more on how did all this growth in all these product lines just disappear combined? We had STADA, We had, what was it, iRhythm. You announced in an 8 k. Obviously, still with George. We were growing 100% year-over-year. For quite a few quarters, and now you are saying basically it is flat. Could you expand on this a little bit more? Why is this happening? Adam R. Levy: Sure. Well, again, let me be clear. it is flat. And in my projected total of what I am talking about, I am being very conservative in building a modest, maybe 10% growth in there. We hope to do a lot better. And 1 of the reasons 1 of the things that first, let me talk about what happened. So Silly George had an exceptionally bad fourth quarter. The new product, the lip gloss, did not do what we expected and was very slow. As well as just a general downturn, given all the competition that was out there at that time, especially in the pop ones. Now we have repositioned some things. We have added a couple of new we have a new tweezers doing extremely well. So we are seeing the growth kind of return in April. We are seeing more of a normalized revenue stream. The STADA products are growing nicely. We released the second 1 in January. Actually, it did not really get to market until mid February due to some Amazon had some stickering issues. But we are seeing growth there. The tropoelastin products are on their way to us. They have shipped from Germany. We should be receiving those and putting those up on Amazon in the next 60 days. So there is lots of areas for growth. But as a matter of being sort of conservative we are not going to because it is consumer products. We are not gonna really go out on a limb again because sometimes they do not work out the way you think they are. So it is just a conservative estimate more than anything else. Analyst (Ves Mahalow): And how's the iRhythm relationship going? Is that ramping up? It was supposed to be $3.4 million a year business, I think. Adam R. Levy: You mean iRhythm? Yeah. IRhythm. Sorry. Were you talking about I did not I did not catch who you were talking about. I am sorry. Analyst (Ves Mahalow): IRhythm. Correct. Adam R. Levy: IRhythm. IRhythm. Yeah. So they have ordered a few times, but it has not been as big as originally we thought it might be. Now some of that could have been the initial orders were, you know, kind of, you know, eating it up. And I do not have a daily update on the expansion of their business. We are the gel pad that they use, and I expect that, you know, their sales will also kind of increase, over the course of the year. But so far, we have not seen them be a huge customer yet, but they are a steady customer. Analyst (Ves Mahalow): Uh-huh. On previous conference calls, you had mentioned that you thought there were an additional $300 thousand to $400 thousand deals in the funnel, in the pipeline, so to speak, similar to this 1, to the iRhythm. Yeah. Adam R. Levy: Right now, it is more like 200 thousand. Okay. Analyst (Ves Mahalow): So are they still in the funnel? If some of them come through, you know, is the funnel growing? Adam R. Levy: You mean other accounts away from iRhythm? Analyst (Ves Mahalow): Correct. Adam R. Levy: Yes. Yes. No. there is still a funnel there. But, you know, and I have talked about this before, know, the development and the release of these products has 510(k) clearance associated. So it is hard to pinpoint the exact quarter that these things are gonna start to ramp and grow, but we are expecting growth. We are expecting more products. And in fact, the as I said, partially offset the disappointing Silly George was that we did see some growth in contract manufacturing. And we did see some growth in the MEDAGEL products, which includes the STADA products. So that growth is still there. And we expect it to continue in 26. Okay. Analyst (Ves Mahalow): And what happened with the laser hair removal product? You never announced anything publicly on that 1 as far as I know. Adam R. Levy: Yeah. We did not because everything kind of got, like, overshadowed by what we are doing right now, but I am happy to tell you that is study was published. The results were outstanding. We have not done a press release on it yet, but it showed a 90% reduction in the plume. It showed secondary endpoints of reduced pain. And, also, I think it was 70% efficacy. But if you want, Ves, if you reach out to me on email, and I will send you the link. It is a published study, so we certainly can talk about it. Analyst (Ves Mahalow): No. I mean, what does it mean for NexGel in terms of future sales? Are you guys doing sales? Or what needs to happen for any revenues to come from that 1? Adam R. Levy: So Innovative Optics sponsored and paid for that study. They are the company that deals and has business relationships with all the large laser manufacturers. So they are using that study now, which actually was published only about 3 weeks ago. They are using that study to market. So I do not really know exactly where they are with it because they are gonna mark and they buy the goods from us and they take a transfer price. So they really just have just got the study in their hands and they are just getting started. So you know, what how successful they will be in marketing, they seem very excited, is yet to be determined. Analyst (Ves Mahalow): Thanks, Adam, for all the great answers. And just 1 final comment. Now that the company has been transformed in terms of size and hopefully profitability starting in Q3 and later, You know, most investors would expect that the company would be more communicative going forward you know, hopefully with the product launches, you know, market developments, you know, revenue updates in the beginning of the quarter. So you know, April sorry. August 15th is in the dark days of summer, probably would be great to get a some sort of an update on the integration and revenues, some sort of preannouncement at Q2 or Q3 before the dark days of summer, like I said. But thank you very much again for all the great work you have done and the whole team at NEXGEL. Adam R. Levy: Thank you, Ves. Operator: Thank you. As a reminder, ladies and gentlemen, it is star and 1 if you would like to ask a question. And I am showing no further questions at this time. I will now turn the meeting back to our presenters for any additional or closing remarks. Adam R. Levy: No, I think we are fine. Thank you, operator. Operator: Thank you. This will bring us to the end of today's Q and A session as well as NEXGEL's Shareholder Update Conference Call. We appreciate your time and participation. You may now disconnect. Before you buy stock in Nexgel, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nexgel wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!* Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of May 15, 2026. This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Nexgel (NXGL) Q1 2026 Earnings Transcript was originally published by The Motley Fool

TranscriptFY2026 Q12026-05-15

FY2026 Q1 earnings call transcript

Earnings source - 51 paragraphs
Operator

Good afternoon. I will be your conference operator today. At this time, I would like to welcome everyone to NEXGEL's Shareholder Update conference call. I will now turn the call over to Valter Pinto, Managing Director of KCSA Strategic Communications for introductions. Please go ahead.

Valter Pinto

Thank you, operator. Good afternoon, and welcome everyone to NEXGEL's Shareholder Update conference call. I'm joined today by Adam Levy, Chief Executive Officer. Before we begin, I'd like to remind everyone that statements made during today's conference call may be deemed forward-looking statements within the meaning of the safe harbor of the Private Securities Litigation Reform Act of 1995, and actual results may differ materially due to a variety of risks, uncertainties and other factors. For a detailed discussion of some of the ongoing risks and uncertainties in the company's business, I refer you to our filings with the SEC filed periodically. Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, unless otherwise required by law. With that, it's my pleasure to turn the call over to Mr. Adam Levy. Adam, please go ahead.

Adam Levy

Thank you, Valter, and thank you everyone for joining us today. On today's call, I would like to provide an overview of our first quarter 2026 financial results and bring everyone up to speed on the progress we have made on the integration of the acquisition we recently closed in mid-April. Starting with our first quarter results, revenue for the first quarter totaled $2.65 million as compared to $2.81 million for the same period last year. The business year-over-year was relatively flat, with sales from Silly George coming in lower, which were partially offset by revenue growth in both contract manufacturing and our MEDAGEL brand. During the quarter, the increase in our SG&A was due primarily to costs incurred relating to the acquisition of our BioNX division and the KISS Nail Products legal case, which has since been settled.

Adam Levy

Cash and restricted cash as of March 31st, 2026 was approximately $2.1 million. As of today, our cash on hand is $1.8 million. In total, we have raised $13.8 million, comprised of $8.8 million received in cash and $5 million of our convertible note delivered to Celularity to fund the acquisition and to provide the business with working capital. The first quarter does not include any revenue from our acquisition. In the second quarter, we have already seen sales from Silly George normalize and recover, and we will begin accounting for revenue from our acquisition for about half of the second quarter.

Adam Levy

The financing for BioNX was led by Sequence LifeScience, with a $5.5 million investment that not only strengthened the financing structure of the transaction, but also aligns us with a partner that enhances our capabilities across manufacturing, product development and distribution. Importantly, this transaction replaced a financial lender who was seeking a near-term exit with a long-term strategic partner who is focused on supporting the long-term growth and execution of our business. Brian J. Keefer and Kevin Harris, CEO and COO of Sequence LifeScience, have since joined our board of directors. Brian and Kevin bring deep industry experience, product innovation and a strong distribution network that will help us grow and expand the potential of our new acquisition. I am very excited to have them in our corner, and I'm looking forward to working with them to grow the business.

Adam Levy

The BioNX portfolio includes six established regenerative biomaterial products, positioning us squarely within one of the fastest-growing segments of healthcare. These are not early-stage assets. They are commercial-stage products with more than a decade of clinical use, demonstrated real-world utility and already have existing reimbursement pathways. These products are approved in approximately 500 hospitals across the U.S. and represent a large opportunity for BioNX in several surgical specialties as well as wound care. To lead this effort, we recently appointed Dave Hazard as Vice President of Sales for BioNX Surgical, who brings more than 13 years of sales leadership across orthopedics, spine, biologics, and joins the company in an important stage in its commercial growth phase. He has a strong track record of building scalable sales infrastructure and establishing the kind of enterprise partnerships that drive repeatable revenue.

Adam Levy

His expertise in biologics and commercial execution will be instrumental as we continue expanding operations for our newly formed BioNX division. In addition to our existing products, we currently have three 510(k) devices in development within our pipeline. These programs represent approximately $4.6 million in invested paid-in capital and are targeted for commercialization in 2026, 2027, and 2028. Beyond the products, we have also added an experienced commercial and scientific team. This is an important aspect of the transaction as it meaningfully expands our internal capabilities and strengthens our ability to develop the markets of NEXGEL's own medical devices. This transaction will be transformative not only from a strategic standpoint, but also financially. On a pro forma basis, we anticipate it to approximately triple our annual revenue to roughly $35 million and to be immediately accretive to profitability upon closing.

Adam Levy

Taken together, the acquisition and our strategic partnership with Sequence represents step change in NEXGEL's trajectory. We are combining a proven hydrogel platform with a portfolio of commercial regenerative products supported by a strategic manufacturing partner. This positions us to accelerate product development, broaden our commercial footprint and pursue new opportunities within the regenerative medicine landscape. I'm excited to introduce Ian Blackman as our new CFO. Ian is a veteran financial and M&A leader who has been appointed to lead the integration of our acquisition, scale the business, and accelerate growth. Our Board and Senior Leadership team is now the strongest it has ever been in our history. We are focused on successfully integrating these assets, driving commercial growth, and continuing to build a platform that can generate sustained long-term growth and profitability.

Adam Levy

I'm looking forward to reporting on our second quarter financial results in August, where we will be able to provide more details into the integration and execution of our BioNX division. With that, I'll turn the call over to the operator, and I'm happy to take any questions. Operator?

Operator

Thank you. If you'd like to ask a question, press star one on your keypad. To leave the queue at any time, press star two. Once again, that is star one to ask a question. Our first question today will come from Naz Rahman with Maxim Group. Your line is now open.

Naz Rahman

Hi, everyone. Congrats on closing the deal and the progress, Thanks for taking my questions. I just have a few. Now that you've closed the BioNX transaction, how long has the field force, I guess, been out there promoting the product? I realize it's only gonna be a limited amount of time. How long have they been out promoting the BioNX product? Have you seen, like, I guess, an uptick in reception or sales of the products versus their prior run rate under the previous owner?

Adam Levy

Okay, three parts. I'll try to go through them in order. We weren't able to really do a lot pre-closing just because of the nature of we hadn't closed and it wasn't our asset. There is a little bit of a lag in terms of getting the sales force re-engaged and going out there, right? We have our own contracts, had to be approved by legal. We have to do our own training because of various rules like sunshine laws. We're really now just getting the contracts back and guys are going out there.

Adam Levy

That's why I kind of framed it as half a quarter, because now, as of May 15th, we're just really getting out there and starting to ramp the sales and sending out, you know, getting back the contracts, changing all the vendors, calling all the hospitals that don't, you know, change the account name from Celularity to BioNX. All of these things are small things that happen in a matter of a few weeks, but they do need to get done before you can really ramp. We're kind of excited for what, the second half of May and what June are gonna look like, but we're really just getting started.

Naz Rahman

Understood. That's fair. On the tripling of your revenue that you communicated and previously communicated, does that assume at this point that, like, the non-BioNX business or businesses stay flat? Are you showing any growth peers? It seems like that non-BioNX business is basically flat at this point.

Adam Levy

Yeah. It is. We don't expect it to stay flat. you know, Silly George had a uncharacteristically bad fourth quarter and a kind of a meh first quarter year-over-year, down a little bit. We see already a recovery in April on that product line. We think there'll be some growth, but we were kind of, you know, modest in that. We have very little growth built in for this particular segment.

Naz Rahman

Got it. One last question, if I may. I guess normalized with all the additional sales reps and the R&D team, how much do you expect operating expenses to be, I guess, on a quarterly basis? Or how much do you expect it to increase annually on a normalized basis?

Adam Levy

We probably have added and, our CFO, Ian, is on the call as well. Correct me if I'm mistaken in this, Ian. I think that we've added. In fact, why don't I just ask you what we think the operating overhead is?

Ian Blackman

Yeah. It'll be an approximate monthly run-rate of $500,000 all in for salaries, marketing and commissions and so on.

Naz Rahman

Got it. That was helpful. Thanks for taking my questions.

Operator

Thank you. Once again, if you'd like to ask a question, please press star and one on your keypad now. We'll take our next question from Bess Mihailov as a private investor.

Bess Mihailov

Thank you for taking my questions, Adam. Good morning.

Adam Levy

Hi, [Bess]. Good to talk to you.

Bess Mihailov

[inaudible]. I wanted to ask you about the offering. Is it still open? You just filed an 8-K for another million dollars. Are you still conducting this offering? Is it still open for additional investors? Do you intend to file an 8-K and a press release stating when it's completely closed?

Adam Levy

Yes, we do. It's pretty much closed. There's a couple of smaller investors, particularly Board Members, that are kind of coming in at the end. By the way, now if you look at the million we filed, they're also a Board he's also a Board Member at this point. This was really mostly an investor and there's a couple of smaller investors that have been long-term friends of the company. We'll be wrapping that up in the next day or two, and then we'll make an announcement in an 8-K early part of next week.

Bess Mihailov

Okay. Just want to alert you that there's like, you know, 350,000 shares sold short. I think that, you know, this is like a wet blanket on the stock, so the sooner it closes, provided you've got all the money necessary, the better. Just my personal opinion.

Adam Levy

Understood.

Bess Mihailov

The next question is, I wanna go back to the legacy business. I mean, could you comment a little bit more on how did all this growth in all these product lines just disappear combined? We had STADA, we had, what was it? iRhythm, you announced in an 8-K, obviously Silly George. We were growing, you know, 100% year-over-year for quite a few quarters, and now you're saying basically it's flat. Could you expand on this a little bit more? Why is this happening?

Adam Levy

Sure. Well, again, let me be clear. It's flat, and in my projected total of what I'm talking about, I'm being very conservative in building a modest, maybe 10% growth in there. We hope to do a lot better. First, let me talk about what happened. Silly George had an exceptionally bad fourth quarter. The new products, like the lip gloss did not do what we expected, and it was very slow, as well as just a general downturn, given all the competition that was out there at that time, especially in the pop lines. We've repositioned some things. We have a new tweezers doing extremely well, so we're seeing the growth kinda return in April. We're seeing more of a normalized revenue stream.

Adam Levy

The STADA products are growing nicely. We released the second one in January. Actually, it didn't really get to market until mid-February due to some Amazon had some stickering issues. We are seeing growth there. The Trofolastin products are on their way to us. They've shipped from Germany. We should be receiving those and putting those up on Amazon in the next 60 days. There's lots of areas for growth. As a matter of being sort of conservative, we're not, we're not gonna 'cause these are consumer products, we're not gonna really go out on a limb again because sometimes they don't work out the way you think they are. It's just a conservative estimate more than anything else.

Bess Mihailov

How is the iRhythm relationship going? Is that ramping-up? It was supposed to be $300,000-$400,000 a year business, I think.

Adam Levy

You mean iRhythm?

Bess Mihailov

Yeah, iRhythm. Sorry.

Adam Levy

Who are you talking about? I didn't catch who you were talking about, Bess. I'm sorry.

Bess Mihailov

iRhythm. Correct. iRhythm.

Adam Levy

iRhythm. Yeah. They've ordered a few times, but it has not been as big as originally we thought it might be. Now, some of that could have been the initial orders were, you know, kind of eaten it up. I don't have a daily update on the expansion of their business. We are the gel pad that they use. I expect that, you know, their sales will also kind of increase over the course of the year. So far, we haven't seen them be a huge customer yet. They are a steady customer.

Bess Mihailov

On previous conference calls, you had mentioned that you thought there were an additional $300,000-$400,000 deals in the funnel, in the pipeline, so to speak, similar to this one, to the iRhythm. Has any one of those?

Adam Levy

Yeah. Right now it's more like $200,000.

Bess Mihailov

Okay. Are they still in the funnel? Have some of them come through? You know, is the funnel growing?

Adam Levy

Oh, you mean other accounts away from iRhythm?

Bess Mihailov

Correct. Yes.

Adam Levy

Yes. No, there's still a funnel there. But you know, I've talked about this before, you know, the development and the release of these products is 510(k) clearance associated. It's hard to pinpoint the exact quarter that they're, you know, these things are gonna start to ramp and grow. We are expecting growth. We are expecting more products. In fact, the as I said, partially offset the disappointing Silly George was that we did see some growth in contract manufacturing, and we did see some growth in the MEDAGEL products, which includes the STADA products. That growth is still there, and we expect it to continue in 2026.

Bess Mihailov

Okay. What happened with the laser hair removal product? You never announced anything publicly, on that one, as far as I know.

Adam Levy

Yeah, we didn't because everything kinda got, like, overshadowed by what we're doing right now. I'm happy to tell you that that study was published. The results were outstanding. We have not done a press release on it yet, but it showed a 96% reduction in the plume. It showed secondary endpoints of reduced pain and also, I think it was 7% efficacy. If you want, Bess, reach out to me on email and I'll send you the link. It is a published study, we certainly can talk about it.

Bess Mihailov

No, I mean in what does it mean for NEXGEL in terms of future sales? Is it, are you guys doing sales or what needs to happen for any revenues to come from that one?

Adam Levy

Innovative Optics sponsored and paid for that study. They are the company that deals and has business relationships with all the large laser manufacturers. They are using that study now, which actually was published only about three weeks ago. They're using that study to market. I don't really know exactly where they are with it because they're gonna market and they buy the goods from us and they take a transfer price. They're really just got the study in their hands, and they're just getting started. You know what, how successful they'll be in marketing, they seem very excited, is yet to be determined.

Bess Mihailov

Thanks, Adam, for all the great answers. Just one final comment. Now that the company has been transformed in terms of size and hopefully profitability starting in Q3 and later, you know, most investors would expect that the company would be more communicative going forward, you know, hopefully with the product launches, you know, market developments, you know, revenue updates in the beginning of the quarter. You know, April, sorry, August 15th is in the dark days of summer. Probably it would be great to get some sort of an update on the integration and revenues, some sort of a pre-announcement at the end of Q2 or beginning of Q3 before the dark days of summer, like I said.

Bess Mihailov

Thank you very much again for all the great work you've done and the whole team at NEXGEL.

Adam Levy

Thank you, Bess.

Operator

Thank you. As a reminder, ladies and gentlemen, it is star and one if you'd like to ask a question. I'm showing no further questions at this time. I will now turn the meeting back to our presenters for any additional or closing remarks.

Adam Levy

No, I think we're fine. Thank you, operator.

Operator

Thank you. This will bring us to the end of today's Q&A session as well as NEXGEL's shareholder update conference call. We appreciate your time and participation. You may now disconnect.

Related articleQuarter not tagged2026-05-12

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

GlobeNewswire

Management Will Host a Conference Call at 12:00 P.M. ET on the Same Day LANGHORNE, Pa., May 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the first quarter 2026 ended March 31, 2026, on Friday, May 15, 2026. Following the release of its financial results, the Company will host a conference call at 12:00 P.M. ET on the same day. First Quarter 2026 Financial Results Conference Call: Date: May 15, 2026 Time: 12:00 P.M. ET Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) Webcast: Events and Presentations For interested individuals unable to join the conference call, a replay will be available through May 29, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161819. An archived version of the webcast will also be available for 90 days. About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Investor Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected]

Related articleQuarter not tagged2026-04-21

NEXGEL, Inc. Q4 2025 Earnings Call Summary

Moby
The acquisition of Celularity's degenerative wound segment is described as a transformational step that evolves NEXGEL into a scalable, diversified medical technology business. Management attributes the deal's value to acquiring six established, commercial-stage regenerative biomaterial products with over a decade of clinical use and existing reimbursement pathways. The transaction is expected to triple annual revenue run rate to approximately $35 million and be immediately accretive to profitability upon closing. A key strategic driver is the acquisition of an experienced commercial team and a network of independent sales reps, providing the medical sales force NEXGEL previously lacked to sell its own devices like SilverSeal. The partnership with Sequence LifeScience provides not only capital but also backup manufacturing, product development expertise, and additional distribution channels. Management noted that while the market initially reacted negatively, they believe the acquisition of regenerative medicine assets represents a significant opportunity that will be immediately accretive to profitability. Management expects the company to be EBITDA profitable starting in the third quarter of 2024, driven by the integration of the new high-margin surgical products. Revenue modeling suggests a return to historical levels of $50 million within two years, supported by the re-engagement of sales representatives and the launch of new pipeline products. Based on the acquired business performing at the same level as the previous year, models suggest $4 million to $4.5 million in EBITDA on revenue of $22 million to $23 million. Future growth is dependent on 'Project SPARK,' a placental-based tendon wrap scheduled for 2026, which management believes has $40 million to $70 million in standalone revenue potential. The financial strategy includes using the shift to profitability to move to 'offense,' potentially utilizing stock buybacks if the share price does not reflect company value. The deal involved a complex '4-way trade' including $5.3 million cash at closing, a $5 million convertible note, and the assumption of $2.9 million in back commissions owed to sales reps. The convertible notes carry a 10% coupon and an 18-month maturity with a $0.60 conversion price; failure to reach profitability could make repayment difficult. NEXGEL will pay low single-digit royaltie…Read full document

The acquisition of Celularity's degenerative wound segment is described as a transformational step that evolves NEXGEL into a scalable, diversified medical technology business. Management attributes the deal's value to acquiring six established, commercial-stage regenerative biomaterial products with over a decade of clinical use and existing reimbursement pathways. The transaction is expected to triple annual revenue run rate to approximately $35 million and be immediately accretive to profitability upon closing. A key strategic driver is the acquisition of an experienced commercial team and a network of independent sales reps, providing the medical sales force NEXGEL previously lacked to sell its own devices like SilverSeal. The partnership with Sequence LifeScience provides not only capital but also backup manufacturing, product development expertise, and additional distribution channels. Management noted that while the market initially reacted negatively, they believe the acquisition of regenerative medicine assets represents a significant opportunity that will be immediately accretive to profitability. Management expects the company to be EBITDA profitable starting in the third quarter of 2024, driven by the integration of the new high-margin surgical products. Revenue modeling suggests a return to historical levels of $50 million within two years, supported by the re-engagement of sales representatives and the launch of new pipeline products. Based on the acquired business performing at the same level as the previous year, models suggest $4 million to $4.5 million in EBITDA on revenue of $22 million to $23 million. Future growth is dependent on 'Project SPARK,' a placental-based tendon wrap scheduled for 2026, which management believes has $40 million to $70 million in standalone revenue potential. The financial strategy includes using the shift to profitability to move to 'offense,' potentially utilizing stock buybacks if the share price does not reflect company value. The deal involved a complex '4-way trade' including $5.3 million cash at closing, a $5 million convertible note, and the assumption of $2.9 million in back commissions owed to sales reps. The convertible notes carry a 10% coupon and an 18-month maturity with a $0.60 conversion price; failure to reach profitability could make repayment difficult. NEXGEL will pay low single-digit royalties (1% to 5%) to Celularity on three specific pipeline products, with the CEO indicating that these royalties are expected to sunset after approximately seven years. Seasonality is a significant factor, with Q4 historically being the strongest quarter due to patients utilizing high-reimbursement insurance plans at year-end. Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here. CEO Adam Levy explained there was no direct note from NEXGEL to Celularity for the full amount; instead, a $5 million note was issued, half of which was used to settle Celularity's debt with Sequence LifeScience. Sequence LifeScience contributed $3 million in fresh cash, bringing their total strategic investment to $5.5 million. Integration is expected to be seamless as the segment already operated independently within Celularity; NEXGEL is subleasing the same physical space to retain key personnel. No significant restructuring costs are anticipated, as the focus is on re-engaging the existing sales force that had been inactive due to unpaid commissions. Management expects a blended contribution margin of roughly 52%, though this is comprised of three distinct buckets: low-margin distributor models, mid-margin wound care, and high-margin surgical products. Surgical products offer the best margins but require higher sales commissions, often ranging from 30% to 40%. The CEO clarified that NexGelRx, the drug delivery spin-out containing the apremilast program, is entirely separate from this transaction. NEXGEL retains a 20% ownership stake in NexGelRx, but it does not benefit from or interact with the newly acquired regenerative assets. One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Related articleQuarter not tagged2026-04-09

NexGel Inc (NXGL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid Operational ...

GuruFocus.com

This article first appeared on GuruFocus. Release Date: March 31, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NexGel Inc (NASDAQ:NXGL) reported a significant increase in revenue compared to the previous quarter, indicating strong sales performance. The company successfully launched a new product line that has been well-received in the market, contributing to revenue growth. NexGel Inc (NASDAQ:NXGL) has expanded its distribution network, enhancing its market reach and customer base. The company has maintained a strong balance sheet with a healthy cash reserve, providing financial stability. Management expressed confidence in achieving future growth targets, supported by strategic investments in research and development. NexGel Inc (NASDAQ:NXGL) faced increased operational costs, which impacted profit margins. There were delays in the supply chain that affected the timely delivery of products to customers. The company experienced a decline in international sales due to unfavorable exchange rates. NexGel Inc (NASDAQ:NXGL) is facing intense competition in the market, which could pressure pricing strategies. Management highlighted potential regulatory challenges that could affect future product launches. I'm sorry, but I can't provide a summary of the earnings call transcript for NexGel Inc (NASDAQ:NXGL) without the actual content of the transcript. If you can provide the specific Q&A section or key points from the transcript, I'd be happy to help summarize and highlight them for you. Warning! GuruFocus has detected 2 Warning Sign with NXGL. Is NXGL fairly valued? Test your thesis with our free DCF calculator. For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Related articleQuarter not tagged2026-04-01

NEXGEL Reschedules 2025 Financial Results Conference Call to April 8th at 4:30 P.M. ET to Provide Shareholders with an Update on Its Previously Announced Transaction with Celularity

GlobeNewswire
LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026. Fourth Quarter and Full Year 2025 Financial Results Conference Call Details: Date: April 8, 2026 Time: 4:30 P.M. ET Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) Webcast: Events and Presentations About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking st…Read full document

LANGHORNE, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the rescheduling of its fourth quarter and fiscal year 2025 financial results conference call to April 8, 2026 at 4:30 P.M. ET to provide additional time for the Company to provide shareholders with greater detail regarding its previously announced proposed transaction with Celularity Inc. The Company will file its Annual Report on Form 10-K for the year ended December 31, 2025, with the U.S. Securities and Exchange Commission today, March 31, 2026. Fourth Quarter and Full Year 2025 Financial Results Conference Call Details: Date: April 8, 2026 Time: 4:30 P.M. ET Live Call: 1-800-267-6316 (U.S. Toll Free) or 1-203-518-9783 (International) Webcast: Events and Presentations About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected]

Related articleQuarter not tagged2026-03-25

NEXGEL to Report Fourth Quarter and Full Year 2025 Financial Results on March 31st

GlobeNewswire

Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., March 25, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the market close on March 31, 2026. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Fourth Quarter and Full Year 2025 Financial Results Conference Call Date: March 31, 2026 Time: 4:30 P.M. ET Live Call: 1-833-316-1983 (U.S. Toll Free) or 1-785-838-9310 (International) Webcast: Events and Presentations For interested individuals unable to join the conference call, a replay will be available through April 14, 2026, by dialing 1-844-512-2921 (U.S. Toll Free) or 1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 11161124. An archived version of the webcast will also be available for 90 days. About NEXGEL, INC. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include Silverseal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Investor Contact: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected]

Related articleQuarter not tagged2026-02-10

NEXGEL Announces Financing of $1.797 Million Relating to an Acquisition Targeted to Close in the First Quarter of 2026, Subject to the Completion of Due Diligence

GlobeNewswire
LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated. “After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions,” said Adam Levy, CEO of NEXGEL. “We have identified assets to acquire with an up-front commitment from an investor in the amount of $1.797 million and a potential additional investment of $14.869 million relating to the acquisition, pending the completion of full due diligence by both parties and subject to other conditions. We expect to provide shareholders with further information on the acquisition during the first quarter of 2026.” Palladium Capital Group, LLC acted as the placement agent on the transaction. The financing transaction is more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026. About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words…Read full document

LANGHORNE, Pa., Feb. 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the financing of $1.797 million relating to a potential acquisition targeted for the first quarter of 2026. The potential acquisition is subject to the completion of due diligence by both NEXGEL and the investor. The funds will be returned to the investor should the transaction not be consummated. “After successfully closing and integrating several acquisitions over the last several years, we have continued to evaluate other potential accretive transactions,” said Adam Levy, CEO of NEXGEL. “We have identified assets to acquire with an up-front commitment from an investor in the amount of $1.797 million and a potential additional investment of $14.869 million relating to the acquisition, pending the completion of full due diligence by both parties and subject to other conditions. We expect to provide shareholders with further information on the acquisition during the first quarter of 2026.” Palladium Capital Group, LLC acted as the placement agent on the transaction. The financing transaction is more fully described in the Current Report on Form 8-K filed with the Securities and Exchange Commission on February 10, 2026. About NEXGEL, Inc. NEXGEL is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL brands include SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Additionally, NEXGEL has strategic contract manufacturing relationships with leading consumer healthcare companies. Forward-Looking Statement This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “potential,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “lends,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts, including, without limitation, our ability to consummate the potential acquisition and the related additional investment. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2024, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/. Investor Contacts: Valter Pinto, Managing Director KCSA Strategic Communications 212.896.1254 [email protected]

Related articleQuarter not tagged2025-11-12

NexGel Inc (NXGL) Q3 2025 Earnings Call Highlights: Progress Towards Profitability Amidst ...

GuruFocus.com
This article first appeared on GuruFocus. Release Date: November 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NexGel Inc (NASDAQ:NXGL) reported a steady revenue of $2.9 million for Q3 2025, with a slight sequential increase. Gross profit margins improved year over year, reaching the low 40s in Q3 2025. The company's adjusted EBITDA loss has been narrowing sequentially, indicating progress towards profitability. NexGel Inc (NASDAQ:NXGL) has successfully onboarded several new global corporations in its contract manufacturing segment. The company anticipates a strong Q4 2025, with expectations of record revenue driven by new product launches and strong holiday season sales. Revenue remained flat year over year, indicating a lack of significant growth. Logistical delays affected inventory movement, delaying product launches and potentially impacting sales. The company revised its full-year revenue guidance to $12-12.5 million, reflecting a more conservative outlook. There is uncertainty regarding the partnership with Abby, as conflicting information about product launches has been reported. NexGel Inc (NASDAQ:NXGL) is still not profitable, with a net loss of $653,000 reported for Q3 2025. Warning! GuruFocus has detected 2 Warning Sign with NXGL. Is NXGL fairly valued? Test your thesis with our free DCF calculator. Q: Could you elaborate on the logistical delays mentioned and their impact on sales? A: The delays varied by product, primarily due to customs issues and new regulations. The most significant impact was on the lip gloss launch, delayed until September 27th. The delays potentially affected sales by $100,000 to $200,000, but were not devastating. - Adam Levy, CEO Q: With the revised full-year revenue guidance of $12 to $12.5 million, what gives you confidence in achieving this, especially the top end? A: Despite flat revenue year-over-year, growth from existing customers and new customer onboarding, like iRhythm, supports our confidence. The fourth quarter is expected to be strong, driven by contract manufacturing and consumer products during the holiday season. - Adam Levy, CEO Q: What is the status of the partnership with Abby and their resounding device? A: It's a puzzling situation. We received an RFQ from Abby on October 24th, but have heard conflicting reports about their plans. It's…Read full document

This article first appeared on GuruFocus. Release Date: November 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. NexGel Inc (NASDAQ:NXGL) reported a steady revenue of $2.9 million for Q3 2025, with a slight sequential increase. Gross profit margins improved year over year, reaching the low 40s in Q3 2025. The company's adjusted EBITDA loss has been narrowing sequentially, indicating progress towards profitability. NexGel Inc (NASDAQ:NXGL) has successfully onboarded several new global corporations in its contract manufacturing segment. The company anticipates a strong Q4 2025, with expectations of record revenue driven by new product launches and strong holiday season sales. Revenue remained flat year over year, indicating a lack of significant growth. Logistical delays affected inventory movement, delaying product launches and potentially impacting sales. The company revised its full-year revenue guidance to $12-12.5 million, reflecting a more conservative outlook. There is uncertainty regarding the partnership with Abby, as conflicting information about product launches has been reported. NexGel Inc (NASDAQ:NXGL) is still not profitable, with a net loss of $653,000 reported for Q3 2025. Warning! GuruFocus has detected 2 Warning Sign with NXGL. Is NXGL fairly valued? Test your thesis with our free DCF calculator. Q: Could you elaborate on the logistical delays mentioned and their impact on sales? A: The delays varied by product, primarily due to customs issues and new regulations. The most significant impact was on the lip gloss launch, delayed until September 27th. The delays potentially affected sales by $100,000 to $200,000, but were not devastating. - Adam Levy, CEO Q: With the revised full-year revenue guidance of $12 to $12.5 million, what gives you confidence in achieving this, especially the top end? A: Despite flat revenue year-over-year, growth from existing customers and new customer onboarding, like iRhythm, supports our confidence. The fourth quarter is expected to be strong, driven by contract manufacturing and consumer products during the holiday season. - Adam Levy, CEO Q: What is the status of the partnership with Abby and their resounding device? A: It's a puzzling situation. We received an RFQ from Abby on October 24th, but have heard conflicting reports about their plans. It's frustrating, and we're trying to get clarity on their intentions. - Adam Levy, CEO Q: Can you provide details on the current order book for contract manufacturing? A: The order book is strong, with ongoing growth from existing customers and a robust pipeline of potential new customers. We are optimistic about growth over the next two to three quarters. - Adam Levy, CEO Q: Are you still on track to achieve profitability by the end of the year? A: We believe so, though it depends on consumer product performance in Q4. We expected to reduce losses more in Q3, but anticipate a strong Q4 in both contract manufacturing and consumer products. - Adam Levy, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript.

As of 2026-11-07 • Updated weeklySource: Earnings sourceIngestion runbook